PHOENIX, Dec. 11, 2025 /PRNewswire/ -- Phoenix Children's has been designated a network site member of the Pediatric Pulmonary Hypertension Network (PPHNet), joining an elite group of just 14 ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...

Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric ...

Pulmonary arterial hypertension is a devastating disorder characterized by precapillary pulmonary hypertension not caused by respiratory disease, obstruction of the pulmonary arteries, or certain less ...

Blood vessels in the lungs aren't like the others in the body. This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension appears in 25% to 30% of patients with COPD. There are no approved therapies for patients ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Pulmonary hypertension is a serious condition that happens when the blood pressure in the arteries of the lungs is higher ...